These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 15982997)

  • 1. The place of partial agonism in psychiatry: recent developments.
    Ohlsen RI; Pilowsky LS
    J Psychopharmacol; 2005 Jul; 19(4):408-13. PubMed ID: 15982997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of schizophrenia drugs: a focus on dopaminergic systems.
    Nikam SS; Awasthi AK
    Curr Opin Investig Drugs; 2008 Jan; 9(1):37-46. PubMed ID: 18183530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
    Burstein ES; Ma J; Wong S; Gao Y; Pham E; Knapp AE; Nash NR; Olsson R; Davis RE; Hacksell U; Weiner DM; Brann MR
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1278-87. PubMed ID: 16135699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
    Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A; Artaiz I; Innerárity A; Del Olmo E; Castro E; Labeaga L; Pazos A; Orjales A
    Neuropharmacology; 2006 Jul; 51(1):129-40. PubMed ID: 16643965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia.
    Kim SH; Han DH; Joo SY; Min KJ
    Hum Psychopharmacol; 2010 Mar; 25(2):187-90. PubMed ID: 20033907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P; Newman-Tancredi A; Loock T; Cussac D
    Eur J Pharmacol; 2008 Feb; 581(1-2):37-46. PubMed ID: 18190908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist.
    Heinrich JN; Brennan J; Lai MH; Sullivan K; Hornby G; Popiolek M; Jiang LX; Pausch MH; Stack G; Marquis KL; Andree TH
    Eur J Pharmacol; 2006 Dec; 552(1-3):36-45. PubMed ID: 17056032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects.
    Strange PG
    Pharmacol Rev; 2001 Mar; 53(1):119-33. PubMed ID: 11171942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis.
    Kuroki T; Nagao N; Nakahara T
    Prog Brain Res; 2008; 172():199-212. PubMed ID: 18772034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds.
    Depoortère R; Barret-Grévoz C; Bardin L; Newman-Tancredi A
    Eur J Pharmacol; 2008 Nov; 597(1-3):34-8. PubMed ID: 18773888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents.
    Newman AH; Grundt P; Nader MA
    J Med Chem; 2005 Jun; 48(11):3663-79. PubMed ID: 15916415
    [No Abstract]   [Full Text] [Related]  

  • 18. Serotonergic approaches in the development of novel antipsychotics.
    Jones CA; McCreary AC
    Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels.
    Heusler P; Newman-Tancredi A; Castro-Fernandez A; Cussac D
    Neuropharmacology; 2007 Mar; 52(4):1106-13. PubMed ID: 17239906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of antipsychotic drugs on serotonin-1A receptor-mediated disruption of prepulse inhibition.
    van den Buuse M; Gogos A
    J Pharmacol Exp Ther; 2007 Mar; 320(3):1224-36. PubMed ID: 17194799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.